Skip to content
Markets News
Stocks1 min read

Genmab Reports Phase 2 Response Rates for Petosemtamab

Makkler Newsroom
October 26, 2026 · Based on reporting by finanzen.net

Updated trial data showed responses across two treatment lines, with low rates of treatment discontinuation and no treatment-related deaths.

Key takeaways

  • Petosemtamab combinations produced response rates of 75% in first-line and 67% in second-line treatment.
  • Treatment-related discontinuations were 3% to 5%, with no treatment-related deaths reported.

Genmab reported Phase 2 data showing response rates of 75% in first-line and 67% in second-line treatment when petosemtamab was combined with chemotherapy for metastatic colorectal cancer. The company presented the updated results at the European Society for Medical Oncology congress in Madrid.

The analysis covered 79 treated patients. Median follow-up was 5.9 months in the first-line group and 7.1 months in the second-line group. Disease control rates exceeded 93%, according to the report.

Treatment discontinuations due to adverse events ranged from 3% to 5%, and no treatment-related deaths were reported. Genmab said the data support its ongoing Phase 3 LiGeR program.

Topics
GMABPetosemtamab
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.